An official website of the United States government

TitleHere's
& authors
how you know Full text links

Log in

Advanced

Amphetamine positive urine

toxicology screen secondary to
atomoxetine
Joshua L Fenderson et al. Case Rep Psychiatry.
2013.
Free PMC article

Hide details

Case Rep Psychiatry. 2013;2013:381261.

doi: 10.1155/2013/381261. Epub 2013 Jan 30.

Authors
Joshua L Fenderson  1 , Amy N Stratton, 
Jennifer S Domingo, Gerald O Matthews, 
Christopher D Tan

Affiliation
1 Uniformed Services University of the
Health Sciences, 4301 Jones Bridge Road,
Bethesda, MD 20814, USA.

PMID: 23424703
PMCID: PMC3570929
DOI: 10.1155/2013/381261

Full text links Cite …

Abstract
The aim of this paper is to report the first case of
atomoxetine leading to false-positive urine drug
screen. An otherwise healthy 27-year-old female
with a history of attention deficit hyperactivity
disorder (ADHD) treated with atomoxetine had an
acute onset tonic-clonic seizure. On arrival to the
hospital, a urine toxicological drug screen with
immunochemical cloned enzyme donor
immunoassay (CEDIA) was performed. Results
were positive for amphetamines; however, the
presence of these substances could not be
confirmed with urine gas chromatography-mass
spectrometry (GC-MS). She denied any illicit
drug use, herbal medications, or supplements,
and her other prescription medications have not
been previously known to cause a false-positive
result for amphetamines. While stimulant
treatments for ADHD could certainly result in a
positive result on urine screen for amphetamines,
there have been no reports of false-positive
results for amphetamines secondary to patients
using atomoxetine. We implicate atomoxetine,
and/or its metabolites, as a compound or
compounds which may interfere with urine drug
immunoassays leading to false-positive results
for amphetamines CEDIA assays.

Figures

Figure 1 Chemical structure of atomoxetine

and…

Similar articles

Bupropion interference with

immunoassays for amphetamines and
LSD.
Vidal C, et al. Ther Drug Monit. 2007.
PMID: 17529897

A Case of False-positive Amphetamine

Results on Urine Toxicology Testing
Secondary to Imatinib.
Meyers S, et al. J Addict Med. 2021.
PMID: 33181576

False-Positive Amphetamines in Urine

Drug Screens: A Six-Year Review.
Pope JD, et al. J Anal Toxicol. 2022.
PMID: 36367744

Priapism associated with the use of

stimulant medications and atomoxetine
for attention-deficit/hyperactivity
disorder in children.
Eiland LS, et al. Ann Pharmacother. 2014.
PMID: 24982313 Review.

Development and evaluation of an

improved method for screening of
amphetamines.
Shindelman J, et al. J Anal Toxicol. 1999.
PMID: 10517558

See all similar articles

References
1. Ring BJ, Gillespie JS, Eckstein JA, Wrighton
SA. Identification of the human
cytochromes P450 responsible for
atomoxetine metabolism. Drug Metabolism
and Disposition. 2002;30(3):319–323. -
PubMed
2. Sallee FR. Atomoxetine: a different
approach to ADHD.
http://www.jfponline.com/Pages.asp?
AID=633.
3. Sauer JM, Ponsler GD, Mattiuz EL, et al.
Disposition and metabolic fate of
atomoxetine hydrochloride: the role of
CYP2D6 in human disposition and
metabolism. Drug Metabolism and
Disposition. 2003;31(1):98–107. - PubMed
4. Ludolph AG, Udvardi PT, Schaz U, et al.
Atomoxetine acts as an NMDA receptor
blocker in clinically relevant concentrations.
British Journal of Pharmacology.
2010;160(2):283–291. - PMC - PubMed
5. Ledbetter M. Atomoxetine: a novel
treatment for child and adult ADHD.
Neuropsychiatric Disease and Treatment.
2006;2(4):455–466. - PMC - PubMed

Show all 10 references

Related information
MedGen

LinkOut - more resources

Full Text Sources
Europe PubMed Central
Hindawi Limited
PubMed Central

Other Literature Sources

scite Smart Citations

Miscellaneous
NCI CPTAC Assay Portal

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

FOLLOW NCBI

Connect with NLM

National Library of Medicine

8600 Rockville Pike
Bethesda, MD 20894

Web Policies
FOIA
HHS Vulnerability Disclosure

Help
Accessibility
Careers

NLM NIH HHS USA.gov